Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
February 10, 2021 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif., HANGZHOU, China and HOUSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
February 09, 2021 07:10 ET
|
Apollomics, Inc.; Edison Oncology
- Apollomics licenses worldwide rights (ex-China, Hong Kong and Taiwan) to develop and commercialize EO1001 - - EO1001 is an irreversible, pan-erbB inhibitor of EGFR (ErbB1), HER2 (ErbB2) and...
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
January 07, 2021 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China and GAITHERSBURG, Md., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development...
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-102 to Initiate a Phase 1 Study
November 12, 2020 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of new tumor-targeting...
Apollomics, Inc. Closes $124 Million Series C Financing
November 06, 2020 07:10 ET
|
Apollomics, Inc.
- Financing led by Ping An Capital - - Phase 2 SPARTA Trial for APL-101 Now Enrolling - - Phase 3 Clinical Trial to begin in China for APL-106 (Uproleselan) - FOSTER CITY, Calif. and HANGZHOU,...
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia
September 27, 2020 20:05 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Sept. 27, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics, Inc. 宣佈啟動針對 c-MET 抑製劑 APL-101 的 SPARTA 第 2 期臨床試驗
May 21, 2020 21:37 ET
|
Apollomics, Inc.
- 試驗將評估廣泛腫瘤類型的各種 MET 失調 - - 專於具有導致 MET 外顯子 14 跳讀的突變非小細胞肺癌，以及具有擴增性和 MET 融合的腫瘤，包括多形膠質母細胞瘤 - 加州福斯特市和中國杭州, May 22, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc. 是致力發現和開發腫瘤學單一療法和聯合療法的創新生物製藥公司，今天宣佈啟動...
APOLLOMICS（冠科美博）宣布启动C-MET抑制剂APL-101的II期全球多中心临床试验SPARTA
May 21, 2020 07:10 ET
|
Apollomics, Inc.
评估不分肿瘤类型的各种MET失调；聚焦MET 14号外显子跳跃突变的非小细胞肺癌及有MET扩增和融合的肿瘤，包括非小细胞肺癌，多形性胶质母细胞瘤及其他肿瘤 中国杭州市和美国福斯特市报道, May 21, 2020 (GLOBE NEWSWIRE) -- Apollomics,...
Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101
May 21, 2020 07:10 ET
|
Apollomics, Inc.
- Trial will evaluate diverse MET dysregulations across broad tumor types - - Focus on non-small cell lung cancer with a mutation that leads to MET exon 14 skipping, and tumors with...
Apollomics（冠科美博） 从美国 Glycomimetics引进三期突破性疗法急性髓系白血病药物
January 06, 2020 09:30 ET
|
Apollomics, Inc.
中国杭州市、美国罗克维尔市和福斯特市, Jan. 06, 2020 (GLOBE NEWSWIRE) -- 新年伊始，GlycoMimetics , Inc. （纳斯达克: GLYC）和Apollomics, Inc. 宣布就急性髓系白血病治疗药物Uproleselan和 GMI-1687的中国市场独家开发和商业化权利签署合作许可协议。Uproleselan和...